INSR and neurodegenerative disease: Furthermore, the NSO administration lowered the insulin receptor inhibitory effect of IOMe-AG538 by modifying the insulin-signaling pathway and by reducing the levels of advanced glycation end products (AGEs) which are proteins or lipids involved in aging and in the pathogenesis of degenerative diseases, including AD.